NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $0.55 -0.02 (-4.30%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$0.55 +0.00 (+0.27%) As of 10/23/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Co-Diagnostics Stock (NASDAQ:CODX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Co-Diagnostics alerts:Sign Up Key Stats Today's Range$0.53▼$0.5750-Day Range$0.55▼$1.3452-Week Range$0.53▼$46.50Volume283,278 shsAverage Volume396,661 shsMarket Capitalization$3.81 millionP/E RatioN/ADividend YieldN/APrice Target$67.50Consensus RatingModerate Buy Company Overview Co-Diagnostics, Inc. is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company develops and commercializes diagnostic technologies and laboratory tests designed to identify infectious diseases and other medical conditions using polymerase chain reaction (PCR) and related molecular methods. Its core technology is the CoPrimer platform, which is intended to support the development of accurate, cost-efficient molecular diagnostic tests. Co-Diagnostics has marketed tests under the Logix Smart brand, including assays for respiratory and other infectious diseases. The company also developed molecular testing products related to COVID-19 and has pursued diagnostic applications in areas such as tuberculosis, mosquito-borne diseases, women’s health and oncology. Co-Diagnostics was founded in 2013 and serves customers through commercial, laboratory and distribution channels in the United States and international markets. Its products are designed for use by clinical laboratories, healthcare providers and other testing organizations, with availability varying by product, regulatory authorization and geography. Dwight E. Hurst is a co-founder and has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Co-Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCODX MarketRank™: 2.28489227887 of 5 starsCo-Diagnostics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingCo-Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCo-Diagnostics has a consensus price target of $67.50, representing about 12,274.0% upside from its current price of $0.55.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 2 research reports in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Co-Diagnostics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.14% of the float of Co-Diagnostics has been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 37.37%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentCo-Diagnostics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Co-Diagnostics this week, compared to 3 articles on an average week.Search Interest6 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders2.30% of the stock of Co-Diagnostics is held by insiders.Percentage Held by Institutions14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CODX Stock News HeadlinesCo-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing ForumOctober 20, 2026 | prnewswire.comHead to Head Review: Neuphoria Therapeutics (NASDAQ:NEUP) and Co-Diagnostics (NASDAQ:CODX)October 19, 2026 | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)Co-Diagnostics Plans Special Meeting After Quorum ShortfallsOctober 17, 2026 | theglobeandmail.comCo-Diagnostics Highlights PCR Platform Capabilities for Potential Plague DetectionOctober 15, 2026 | prnewswire.comCo-Diagnostics Expands Vector Smart With First Tribal Laboratory InstallationOctober 8, 2026 | rttnews.comCo-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American TribeOctober 8, 2026 | prnewswire.comCo-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne DiseaseOctober 7, 2026 | prnewswire.comSee More Headlines CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $5.56 at the beginning of the year. Since then, CODX shares have decreased by 90.2% and is now trading at $0.5455. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($1.46) EPS for the quarter, topping analysts' consensus estimates of ($3.00) by $1.54. The business had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.13 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 210.99% and a negative net margin of 6,531.77%. Read the conference call transcript. When did Co-Diagnostics' stock split? Shares of Co-Diagnostics reverse split on the morning of Friday, January 2nd 2026.The 1-30 reverse split was announced on Tuesday, December 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), NIO (NIO) and Novavax (NVAX). Company Calendar Last Earnings8/13/2026Today10/23/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (12m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CODX's financial health is in the Red zone, according to TradeSmith. CODX has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CODX CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees115Year Founded2013Price Target and Rating Average Price Target for Co-Diagnostics$67.50 High Price Target$90.00 Low Price Target$45.00 Potential Upside/Downside+12,274.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($10.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.90 million Net Margins-6,531.77% Pretax Margin-6,756.77% Return on Equity-210.99% Return on Assets-174.97% Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.52 Sales & Book Value Annual Sales$620 thousand Price / Sales6.14 Cash FlowN/A Price / Cash FlowN/A Book Value$9.14 per share Price / Book0.06Miscellaneous Outstanding Shares6,980,000Free Float6,820,000Market Cap$3.81 million OptionableNo Data Beta2.90 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CODX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
